Table 3 MRI-based tumor shrinkage patterns association with pCR according to different molecular subtypes in the primary analysis cohort
Shrinkage pattern | HR+/HER2− | HER2+ | TNBC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N (151) | pCR (n = 15) | Non-pCR (n = 136) | p | N (123) | pCR (n = 68) | Non-pCR (n = 55) | p | N (71) | pCR (n = 30) | Non-pCR (n = 41) | p | |
CS | 78 (52%) | 4 (27%) | 74 (54%) | 0.167 | 67 (54%) | 40 (59%) | 27 (49%) | 0.167 | 45 (63%) | 25 (83%) | 20 (49%) | NA |
 CS to small foci | 1 (0.7%) | 1 (6.7%) | 0 (0%) | (CS vs. DIO) | 9 (7.3%) | 9 (13%) | 0 (0%) | (CS vs. DIO) | 3 (4.2%) | 3 (10%) | 0 (0%) | (CS vs. DIO) |
 Simple CS | 74 (49%) | 3 (20%) | 71 (52%) | 0.050 | 50 (41%) | 27 (40%) | 23 (42%) |  < 0.001a | 40 (56%) | 21 (70%) | 19 (46%) |  < 0.001a |
 CS plus decreased enhancement | 3 (2.0%) | 0 (0%) | 3 (2.2%) | (CS vs. SD) | 8 (6.5%) | 4 (5.9%) | 4 (7.3%) | (CS vs. SD) | 2 (2.8%) | 1 (3.3%) | 1 (2.4%) | (CS vs. SD) |
DD | 29 (19%) | 11 (73%) | 18 (13%) |  < 0.001 a | 41 (33%) | 25 (37%) | 16 (29%) | 0.167 | 13 (18%) | 5 (17%) | 8 (20%) | 0.059 |
 CS with surrounding lesions | 7 (4.6%) | 3 (20%) | 4 (2.9%) | (DD vs. CS) | 9 (7.3%) | 4 (5.9%) | 5 (9.1%) | (DD vs. CS) | 5 (7.0%) | 2 (6.7%) | 3 (7.3%) | (DD vs. CS) |
 Residual multinodular lesions | 22 (15%) | 8 (53%) | 14 (10%) |  < 0.001 a (DD vs. SD) | 32 (26%) | 21 (31%) | 11 (20%) |  < 0.001a (DD vs. SD) | 8 (11%) | 3 (10%) | 5 (12%) | 0.007a (DD vs. SD) |
DIO | 3 (2.0%) | 0 (0%) | 3 (2.2%) | 0.089 (DD vs. DIO) | 3 (2.4%) | 2 (2.9%) | 1 (1.8%) | 0.167 (DD vs. DIO) | 0 (0%) | 0 (0%) | 0 (0%) | NA (DD vs. DIO) |
SD | 41 (27%) | 0 (0%) | 41 (30%) | NA (SD vs. DIO) | 12 (10%) | 1 (1.5%) | 11 (20%) | 0.014 (SD vs. DIO) | 13 (18%) | 0 (0%) | 13 (32%) | NA (SD vs. DIO) |